3 unknown, 1 terminated. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Unknown 3, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow rubitecan: new trials by email Literature Review of rubitecan trials Research Report on rubitecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer Rubitecan - Pancreatic Cancer | Phase 2 / Phase 3 | Terminated | Astex Pharmaceuticals, Inc. | 39 | 2005-02-01 | 2024-08-02 |
| Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas fluorouracil, gemcitabine hydrochloride, mitomycin C - Pancreatic Cancer | Phase 3 | Unknown | Astex Pharmaceuticals, Inc. | 1999-03-01 | 2013-12-04 | |
| Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer fluorouracil, rubitecan - Pancreatic Cancer | Phase 3 | Unknown | Astex Pharmaceuticals, Inc. | 1998-11-01 | 2013-12-04 | |
| Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer gemcitabine hydrochloride, rubitecan - Pancreatic Cancer | Phase 3 | Unknown | Astex Pharmaceuticals, Inc. | 1998-11-01 | 2013-12-04 |
Pancreatic Neoplasms (4) · Adenocarcinoma (1)
Astex Pharmaceuticals, Inc. (4)
United States (4)